Addressing unmet clinical needs in complex calcium modification requires exceptional deliverability. Dr. Enrico Cerrato presented a challenging case involving severe calcium in a highly tortuous, small-vessel anatomy — specifically an obtuse marginal (OM) branch. Where traditional IVL catheters often struggle or risk failure in tight tortuosity, the LithiX® HC-IVL 2.0 mm catheter successfully navigated the vessel and effectively fractured the calcium to achieve optimal lumen gain. View the full presentation here: piped.video/LaHCs7lRz3g?si=BtPI…  The LithiX™ HC-IVL system is CE mark approved and is not available for sale in the United States. CAUTION: Case studies shown are based on individual experiences and results may vary. Results depend on a variety of factors, including patient history, severity of condition, and compliance with instructions. Elixir Medical does not claim that these results demonstrate the safety and effectiveness of the device. PMN 2566 Rev A

Elixir Medical will be at @GRCIcardio 2026 in Paris. 📅 September 23–25 📍 Palais des Congrès, Paris, France While you're at the congress, visit the Elixir Medical booth #14 to connect with our team and learn more about our latest innovations in interventional cardiology. Don’t miss these presentations: See how Lithix effectively and safely modifies calcium in complex clinical situations with nodular calcification and tortuous anatomy by @charlottetroui2: • Session: GRCIn - Managing Complexity through Innovation - Ballon de l'extreme • Day: Wednesday, Sept. 23 • Time: 17:10–17:22 • Location: Bordeaux Amphitheater Watch an overview of the modern Coronary Lithotripsy solutions and how the simplicity of LithiX IVL impacts PCI in calcified lesions by Dr. Pierre Robert: • Session: Resistant lesions? Come and test yourself! – Option Lithotripsy • Day: Friday, Sept. 25 • Time: 11:30-11:35 • Location: Studio We look forward to connecting with the interventional cardiology community and sharing the latest from Elixir Medical at GRCI. To see the congress details: grci.fr #GRCI2026 #ElixirMedical #InterventionalCardiology #PCI #Cardiology The LithiX™ HC-IVL system is CE mark approved and is not available for sale in the United States. Muthusamy TS, et al. Hertz contact intravascular lithotripsy for calcified coronary lesions in real-world practice: Primary outcomes of the MY-IVL post-market study. Cardiovasc Revasc Med. 2026 PMN 3014 Rev A

Join Elixir Medical at CINE-LIVE 2026: Cardiac Intervention Newcastle. 📅 September 21–22, 2026 📍 Newcastle upon Tyne, England We look forward to two days of live cases, practical education, and discussion focused on complex coronary intervention. During the meeting, @MohanedEgred will perform live cases featuring two Elixir Medical technologies: • LithiX™ Hertz Contact IVL – safe and effective in highly complex, severe calcification lesions including eccentric and nodular • DynamX® Coronary BioadaptorSystem – representing a major new treatment in PCI by providing restoration of the artery function We look forward to seeing these technologies demonstrated in a live clinical setting and joining the discussion with the interventional cardiology community. Learn more about CINE-LIVE 2026: millbrook-events.co.uk/event… The LithiX HC-IVL system and the DynamX® Coronary BioadaptorSystem are CE mark approved and are not available for sale in the United States. Caution: The DynamX® Sirolimus Eluting Coronary BioadaptorSystem is an investigational device in the United States. Limited by Federal (or United States) law to investigational use. PMN 3013 Rev A

Traditional drug-eluting stents often lead to late lumen loss, but the DynamX® Coronary Bioadaptor System tells a different story. In the DYNAMITE study, which evaluated complex lesions, Dr. Antonio Mangieri demonstrated how DynamX achieves favorable vessel remodeling including late lumen enlargement and preserves lumen area over time. Follow-up at 9 months also confirmed restored physiological vessel motion and normal vasomotion response to stimuli (acetylcholine and nitrates), which is critical for blood flow regulation and vascular tone. View the full presentation here: piped.video/CNeCtSrKk3s?si=7a32…  #EuroPCR2026 #DynamX #Bioadaptor #PCI #Cardiology The DynamX® Coronary Bioadaptor System is CE mark approved and is not available for sale in the United States. Caution: The DynamX® Sirolimus Eluting Coronary Bioadaptor System is an investigational device in the United States. Limited by Federal (or United States) law to investigational use. CAUTION: Case studies shown are based on individual experiences and results may vary. Results depend on a variety of factors, including patient history, severity of condition, and compliance with instructions. Elixir Medical does not claim that these results demonstrate the safety and effectiveness of the device. PMN 2563 Rev A

We’re pleased to announce that DynamX® Sirolimus Eluting Coronary Bioadaptor System has received regulatory approval from Japan’s Ministry of Health, Labour and Welfare (MHLW). This important milestone represents another step forward to bring this innovative solution to physicians and patients around the world. “The DynamX bioadaptor represents a major new treatment in PCI by providing restoration of the artery function,” remarked Shigeru Saito, M.D., principal investigator of BIOADAPTOR RCT trial and Director of the Cardiac Center at Shonan Kamakura General Hospital in Kamakura, Japan. Read the press release: elixirmedical.com/new-cardio… The DynamX® Coronary Bioadaptor System is CE mark approved and is not available for sale in the United States. Caution: The DynamX® Sirolimus Eluting Coronary Bioadaptor System is an investigational device in the United States. Limited by Federal (or United States) law to investigational use.

Kicking off the first week of August with afternoon bingo! On Wednesday, Elixir hosted our monthly lunch, accompanied by a game of bingo. Employees had a chance to play, spectate, and enjoy delicious sandwiches. Six winners went home with prizes.

Cardiovascular Intervention Today – 4 Year Article Additional industry coverage of the BIOADAPTOR-RCT 4-year results is now available from Cardiovascular Intervention Today. Presented at EuroPCR 2026, the data demonstrated durable long-term outcomes with the DynamX® Bioadaptor, including significantly lower target lesion failure rates compared with a contemporary DES and continued follow-up through 4 years. Read more:buff.ly/rqo2Nmj The DynamX® Coronary Bioadaptor System is CE mark approved and is not available for sale in the United States. Caution: The DynamX® Sirolimus Eluting Coronary Bioadaptor System is an investigational device in the United States. Limited by Federal (or United States) law to investigational use. #DynamX #Bioadaptor #EuroPCR2026 #ClinicalData #PCI #Cardiology #ElixirMedical PMN 2546 Rev A

Medtech Insight – 4 Year Article New coverage from Citeline’s Medtech Insight examines the latest 4-year BIOADAPTOR-RCT findings and their implications for the future of coronary intervention. The article highlights long-term clinical outcomes observed with the DynamX® Bioadaptor, including significantly lower event rates compared with a contemporary drug-eluting stent and a substantial reduction in cardiovascular death. Read the full article with a free trial of Citeline:bit.ly/4yIwGCC The DynamX® Coronary Bioadaptor System is CE mark approved and is not available for sale in the United States. Caution: The DynamX® Sirolimus Eluting Coronary Bioadaptor System is an investigational device in the United States. Limited by Federal (or United States) law to investigational use. #DynamX #Bioadaptor #ClinicalData #PCI #Medtech #Cardiology #ElixirMedical PMN 2545 Rev A

Elixir Medical hosted another successful annual backpack drive! Each year, we partner with local organizations to raise money for students to receive new school supplies before the year starts. This summer, we hit 100% of our goal of $3000. CEO Motasim Sirhan did a 2:1 matchup, donating an additional $6000. All together, $9000 will go to the Family Giving Tree Backpack Drive. We thank and appreciate all employees who participated through cash donations or purchased supplies, and Motasim's efforts to ensure students can happily start the school year feeling supported.

Real-world evidence is building in support of bioadaptive technology. At EuroPCR 2026, the Bio-RESTORE study released 30-day outcomes for the first 656 patients enrolled and treated with the DynamX® Coronary Bioadaptor System in routine clinical practice. The study design plans for follow-up through the first year. The study reported: • 100% Device Success • 99.7% Procedural Success • 0.5% TLF Rate As experience with bioadaptor technology continues to expand, physician-led registries such as Bio-RESTORE provide valuable insights that complement randomized clinical trial data. Visit Elixir Medical for more information: bit.ly/4wYjgko #DynamX #Bioadaptor #RealWorldEvidence #PCI #Cardiology #EuroPCR2026 The DynamX® Coronary Bioadaptor System is CE mark approved and is not available for sale in the United States. Caution: The DynamX® Sirolimus Eluting Coronary Bioadaptor System is an investigational device in the United States. Limited by Federal (or United States) law to investigational use. PMN 2485 Rev A

“Elixir’s superpower is its people.” Andrew Richards in Regulatory shared powerful words about Elixir’s company culture. “Each day, I have the opportunity to collaborate with industry experts who bring a wealth of knowledge, creativity, and determination to solving complex challenges. We are advancing vascular medicine and achieving things as a team.” If you are interested in joining our team, visit our Careers page to learn more: bit.ly/4vopQjO

TCTMD - 4-Year Article “The rate of target lesion failure with Bioadaptor was just 2.8%, which astounded many operators.” That statement’s from coverage in TCTMD, highlighting the 4-year results from the BIOADAPTOR-RCT, presented at EuroPCR 2026. The data demonstrated significantly lower rates of target lesion failure with the DynamX® Bioadaptor compared with a contemporary drug-eluting stent, with continued separation of the adverse event curve through 4 years. The findings also showed a significant reduction in cardiovascular death compared to DES, and no new target lesion failure events in the bioadaptor arm between years 3 and 4. Read the article:bit.ly/4gEGVkX The DynamX® Coronary Bioadaptor System is CE mark approved and is not available for sale in the United States. Caution: The DynamX® Sirolimus Eluting Coronary Bioadaptor System is an investigational device in the United States. Limited by Federal (or United States) law to investigational use. #DynamX #Bioadaptor #EuroPCR2026 #PCI #ClinicalData #Cardiology #ElixirMedical PMN 2544 Rev A

Don’t worry if you didn’t get a chance to attend #EuroPCR2026. We’ve got new insights and the latest clinical updates from the largest bioadaptor study so far. Check out this session: “Impact of Imaging, or Physiology-guided PCI on Outcomes with Bioadaptor from INFINITY-SWEDEHEART RCT.” As precision in PCI continues to evolve, physicians are integrating imaging and physiology guidance into their treatment techniques. But regardless of the technique, the mechanism of action of bioadaptor plays a critical role in optimizing long-term results. Explore how this trial measured imaging- and physiology-guided PCI outcomes with bioadaptor technology. View the presentation: bit.ly/4vjK39q #EuroPCR #DynamX #Bioadaptor #PCI #Imaging #Cardiology #ClinicalData Caution: The DynamX® Sirolimus Eluting Coronary Bioadaptor System is an investigational device in the United States. Limited by Federal (or United States) law to investigational use. PMN 2486 Rev A

Happy Fourth of July! As the United States celebrates its 250th anniversary, we honor a legacy of innovation, perseverance, and progress—values that continue to inspire advancements in science, medicine, and technology. Wishing everyone a safe and enjoyable Independence Day. #FourthofJuly #America250 #Innovation #ElixirMedical

We’re hiring: join our mission to reimagine vascular treatments We're growing across multiple teams, including R&D, clinical, and commercial. If you're ready to help bring new thinking to vascular intervention, we’d love to hear from you. Explore open roles: bit.ly/4vHd00h #Careers #Hiring #Medtech #Innovation #ElixirMedical

What drives innovation at Elixir? Our people. Behind every device and data point is a team committed to better patient outcomes. At Elixir, our engineers, chemists & highly skilled production teams bring rigor and passion to solving real-world challenges in vascular intervention. #TeamElixir #InnovationCulture #MedtechCareers

Last week, Elixir Medical welcomed six interns on our annual Intern Meeting Day. Across two days, departmental leaders came and discussed different facets of the company. The interns had the opportunity to listen, observe, and ask questions to gain more knowledge on Elixir’s products and operations. The interns learned how their specific roles and departments support one another. They listened to a variety of practical, clinical, and operational experiences to provide the interns with a strong foundational knowledge for their time at Elixir. Elixir Medical is thrilled to have our interns on board. We are proud to support them through this experience and hope that they advance their interest in medical technology. #ElixirCareers #WorkWithPurpose #MedtechInternships NPMC 373

What happens when two independent randomized controlled trials tell the same story? 3 years of data from BIOADAPTOR RCT. 2 years of data from INFINITY-SWEDEHEART. Both large randomized controlled trials show that the DynamX coronary bioadaptor continues to demonstrate long-term sustained treatment benefits, including reduced adverse events. Watch Dr. David Erlinge present compelling long-term results from the INFINITY-SWEDEHEART RCT: bit.ly/4g0gGoK #DynamX #Bioadaptor #PCI #InterventionalCardiology #ClinicalEvidence The DynamX® Coronary Bioadaptor System is CE mark approved and is not available for sale in the United States. Caution: The DynamX Sirolimus Eluting Coronary Bioadaptor System is an investigational device in the United States. Limited by Federal (or United States) law to investigational use. PMN 2432 Rev A

Why Work at Elixir? If you're looking for a workplace where scientific rigor meets entrepreneurial spirit, Elixir Medical is hiring. Join a team that’s not just inventing devices but transforming how vascular disease is treated worldwide. Visit our Careers page to learn more: bit.ly/4vopQjO #NowHiring #ElixirCareers #MedtechJobs #WorkWithPurpose

A critical moment for PCI! Researchers presented the latest data – 4 years after the procedure – from the BIOADAPTOR RCT at #EuroPCR2026, comparing DynamX bioadaptor to a contemporary drug-eluting stent. The big news: 66% reduction in target lesion failure (TLF) for DynamX bioadaptor compared to DES. We’re excited to see the impact of the bioadaptor’s innovative unlocking technology on patient outcomes. The incidence curve of major adverse cardiac events in the years after PCI really is flattening. #EuroPCR #DynamX #Bioadaptor #RCT #ClinicalData #Cardiology Caution: The DynamX® Sirolimus Eluting Coronary Bioadaptor System is an investigational device in the United States. Limited by Federal (or United States) law to investigational use. PMN 2475 Rev A